Rekombinanter CD22 (Epratuzumab Biosimilar) Antikörper

Produktnummer ABIN5668217

Dieses Kaninchen Chimeric-Antikörper erkennt spezifisch CD22 (Epratuzumab Biosimilar) in BP, FACS und IP. Er zeigt eine Reaktivität gegenüber Human, Cynomolgus und Rhesusaffen.

Kurzübersicht für Rekombinanter CD22 (Epratuzumab Biosimilar) Antikörper (ABIN5668217)

Target: CD22 (Epratuzumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human, Cynomolgus, Rhesusaffen

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Dieser CD22 (Epratuzumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Blocking Peptide (BP), Flow Cytometry (FACS), Immunoprecipitation (IP)

Klon: HL22

Produktdetails anti-CD22 (Epratuzumab Biosimilar) Antikörper

Verwendungszweck: Anti-CD22 [hL22 (Epratuzumab)], Rabbit IgG, kappa

Spezifität: This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.

Kreuzreaktivität: Cynomolgus, Rhesusaffen

Produktmerkmale:

Original Species of Ab: Human

Original Format of Ab: IgG1

Aufreinigung: Protein A affinity purified

Reinheit: > 98 % as determined by SDS-PAGE

Endotoxin-Niveau: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).

Isotyp: IgG kappa

Anwendungsinformationen

Applikationshinweise: Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).

Kommentare:

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu CD22 (Epratuzumab Biosimilar)

Target: CD22 (Epratuzumab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14

UniProt: P20273